

Anti-Inflammatory and Immune Regulatory Effects of *Salvia officinalis* Extract on OVA-induced Asthma in Mice

Abd El-Hamid Mohamed Elwy¹ and GhadaTabl²

¹ Forensic Medicine and Clinical Toxicology Department, Faculty of Medicine, Tanta University

² Zoology Department, Faculty of Science, Tanta University

ghada_tabl@yahoo.com

Abstract: The study designed to evaluate the protective effect of *Salvia officinalis* (SO) water extract against OVA-induced asthma in mice. The OVA-induced asthmatic mice exhibited significant increase in total leukocytes count, IL-4 and IL-5 levels in bronchoalveolar lavage fluid (BALF) and eosinophils count in (BALF), in addition, to the serum total IgE level. Pathological changes in the lung were evaluated and compared to either treated OVA-challenged SO group or control- *Salvia Officinalis* oral administered group. *Salvia Officinalis* extract reduced significantly the number of inflammatory cells and cytokines in the BALF and the level of IgE as compared to OVA-challenged group. Moreover, *Salvia Officinalis* extract (SO) reduced the eosinophils infiltration in the lung tissue. These results suggest that *Salvia officinalis* extract via oral treatment may have anti-inflammatory and immune regulatory effects on bronchial allergic asthma.

[Abd El-Hamid Mohamed Elwy and GhadaTabl. **Anti-Inflammatory and Immune Regulatory Effects of *Salvia officinalis* Extract on OVA-induced Asthma in Mice.** *Life Sci J* 2012;9(2s):191-196]. (ISSN: 1097-8135). <http://www.lifesciencesite.com>. 32

Keywords: *Salvia officinalis* extract- OVA-induced asthma-Leukocytes-Cytokines- Eosinophils-Serum IgE level.

1. Introduction

The genus *Salvia* L. (Lamiaceae), with about 900 species, is one of the most widespread members of the family Lamiaceae. (Longaray Delamare *et al.*, 2007). *Salvia officinalis* (SO), a plant endemic to the Mediterranean region is the most popular herbal remedy in the Middle East to treat common health complications such as cold and abdominal pain (Gali-Muhtasib *et al.*, 2000). *Salvia* species are considered with curative properties (Kintzios, 2000). They possess antiseptic, antibacterial (Soković *et al.*, 2010), antinociceptive and anti-inflammatory (Baricevic *et al.*, 2001; Rodrigues *et al.*, 2012), antiviral (Geuenich *et al.*, 2008), Cytotoxic (Loizzo *et al.*, 2007), spasmolytic, anticonvulsant (Baricevic and Bartol, 2000) in addition, to the antimicrobial and antioxidant activities (Bozin *et al.*, 2007; Abu-Darwish *et al.*, 2012).

Allergic asthma is characterized by airway hyperresponsiveness to specific and/or nonspecific stimuli, chronic pulmonary eosinophilia, elevated serum IgE level, and excessive mucus production (Kuperman *et al.*, 1998). The pathology associated with asthma is thought to be mediated by CD4⁺T lymphocytes producing the type 2 cytokines, IL-4 and IL-5, as both messenger RNA and protein levels of these cytokines are elevated in bronchial biopsies bronchoalveolar lavage (BAL) cells, and blood of allergic proteins as compared to normal individuals. Since these cytokines promote the accumulation and activation of eosinophils as well as IgE synthesis by B cells, this cytokine pattern has been thought to be

important in the pathogenesis of asthma (Wills-Karp, 1999; Renauld, 2001; Elias *et al.*, 2003; Boyce *et al.*, 2012; Lommatzsch, 2012). Asthma is usually divided into allergic asthma and non-allergic asthma, and approximately two-thirds of asthma cases are allergic (Hamelmann, 2007; Bollag *et al.*, 2009). It is widely accepted that antigen-specific T helper cell type 2 (Th2) and their cytokines such as IL-5, IL-4, and IL-13 orchestrate the feature of asthma (Kay, 2001; Boyce *et al.*, 2012).

The study designed to evaluate the protective effects of *salvia officinalis*(SO)water extract on allergic asthma, so we used OVA-induced asthma mouse model which used as a reference method by other investigators (Secor *et al.*, 2008; Yim *et al.*, 2010).

2. Material and Methods

Experimental animals

The study used Balb/c mice weighing 25-35g obtained from Theodor Bilharz Research Institute, AL-Giza Egypt. They were acclimatized to the environment for two weeks prior to experimental use and had access to water and food *ad libitum*. The Laboratory Animal Welfare including environment, housing and management are carried out with recommendations for the proper care and use of laboratory animals of American Association for Accreditation of Laboratory Animal Care (AAALAC) (1996).

Preparation of *Salvia officinalis* L. leaves aqueous extract.

Aqueous extracts were prepared as described previously by Nolkemper *et al.* (2006). Briefly, boiling water (100 ml) was added to dried leaves (10 g) and incubated for 15 min, subsequently filtered and cooled down. The resulting extracts were sterile filtered, aliquoted, and stored at -20°C. The extract was given orally (100 mg/ kg b.wt.).


OVA-Induced Asthmatic Mouse Model

According to the methods described by Henderson *et al.* (1996) and Erb *et al.* (1998) mice were injected intraperitoneally with 2µg OVA chicken egg albumin (Sigma Chemical Co., St. Louis, MO) in 100µl aluminum hydroxide (alum adjuvant) on day 0 (starting time) and boosted again intraperitoneally with 2µg OVA/alum at day 14.

Fourteen days after the second intraperitoneal immunization mice were anesthetized by i.p. injection (0.2 ml) of a mixture of ketamine (0.44mg /ml) and xylazine (6.3mg/ml) then 100µg OVA in a 50 µl volume of phosphate buffered saline (PBS) was administered by intranasal challenge.

Experimental design:

Mice were divided into four groups, the 1st control mice and the 2nd control-*Salvia officinalis* (SO), while the 3rd and 4th groups were underwent OVA exposure as OVA-challenged, and OVA-challenged SO, respectively. The second and fourth groups received *Salvia officinalis* extract (100 mg/kg p.o.) from day 0 to the day of challenge. Sacrificiation of mice was done after 48hrs of intranasal OVA challenge (Figure 1). The blood collected and centrifuged for 10 min. and stored at -80°C.



Figure(1): Diagram of the experimental design

Detection of Different Cell Types in Bronchoalveolar Lavage Fluid

The mouse trachea was cannulated and lungs were washed 3 times with 1ml phosphate buffer saline (PBS). Bronchoalveolar lavage fluid (BALF) cells from a 0.05-ml aliquot of the pooled sample were counted using a hemocytometer to determine the total leukocytes count. The remaining fluid was immediately centrifuged at 4°C for 10 min at 200 g. The supernatant was collected for cytokines measurements, by ELISA. The cell pellets were re-suspended in normal saline containing 10% bovine serum albumin (BSA). BALF cell smears were made on glass slides. The dried slides were stained for eosinophil's count with eosin and methylene blue according to Henderson *et al.* (1996).

Detection of cytokines in BALF

Cytokines, IL-4 and IL-5 were evaluated with an ELISA kit (California, USA) according to the manufacturer's protocol.

Measurement of serum level IgE:

Forty-eight hours post intranasal challenge, animals were sacrificed and Serum IgE was evaluating with an enzyme linked immune sorbent assay (ELISA) using Mouse Serum Anti-OVA IgE Antibody Assay Kit Catalog # 3010 Chondrex, Inc.

Histological analysis

Forty-eight hours after the intranasal challenge, the lungs were removed, washed with PBS and infused with 10% formalin in PBS for fixation. The lung tissue was sectioned and stained with hematoxylin and eosin (H&E)

Statistical analysis

Data were fed to the computer using IBM SPSS software package version 20.0. Quantitative data were described using mean and standard error. Comparison between different groups was analyzed using F-test (ANOVA) and Post Hoc test (Scheffe) for pair wise comparison. Significance test results are quoted as two-tailed probabilities. Significance of the obtained results was judged at the 5% level.

3.Results

Data represented in table (1) showed that the number of total leukocytes and eosinophils cells as well as IL-4 and IL-5 levels in BALF and the serum total IgE were significantly increased in OVA-challenged group

as compared to the control group values. The data of OVA-SO group showed significant decrease in the aforementioned parameters as compared to the corresponding values of OVA-challenged group.

Table (1): Effect of *Salvia officinalis* extract on BALF cells migration, cytokines production (IL-4, IL-5) and IgE level

	control (n=5)	control-SO (n=5)	OVA- challenged (n=5)	OVA-SO challenged (n=5)	<i>p</i>
Total leukocyte (10⁶/ml)	0.43 ± 0.05	0.46 ± 0.05	6.51 ^a ± 0.12	3.22 ^b ± 0.36	<0.001*
Eosinophil (10⁵/ml)	0.25 ± 0.04	0.23 ± 0.01	5.27 ^a ± 0.08	2.32 ^b ± 0.08	<0.001*
IL_4 (pg/ml)	10.4 ± 0.64	10.54 ± 1.14	80.46 ^a ± 0.35	12.40 ^b ± 1.46	<0.001*
IL_5(pg/ml)	11.34 ± 0.58	11.28 ± 0.13	41.22 ^a ± 0.5	13.34 ^b ± 0.13	<0.001*
Total IgE (ng/ml)	14.52 ± 0.66	15.30 ± 1.55	70.26 ^a ± 0.11	13.56 ^b ± 1.79	<0.001*

Salvia officinalis extract was given orally from the first day of immunization to the day of intranasal challenge

Data was expressed in mean ± SE

p: *p* value for F test (ANOVA)

pair wise between any two groups was assessed using Post Hoc test (Scheffe)

a: Significant with control group

b: Significant with OVA- challenged group

*: Statistically significant at *p* ≤ 0.05

Histological analysis

Lungs in the OVA-challenged group showed a large increase in eosinophils recruitment compared to the control group. The lungs of mice treated with

Salvia officinalis (SO) extract showed significantly fewer eosinophils than in the OVA-challenged group (Figure 2).




Figure (2): Histological analysis of mouse lung sections. Mouse lung sections were stained with hematoxylin and eosin. Lung tissue from the OVA challenged-SO mouse group (D) showed fewer eosinophils than the OVA challenged(C), scale bars = 100µm.

4.Discussion

Airway inflammation is the key factor in the pathogenesis of asthma and current strategies for the management focus on suppressing airway inflammation (Kumar, 2001; Walsh, 2006).

In oriental medicine, herb was widely used to treat bronchial asthma (Stockert *et al.*, 2007), theoretically by clearing the pathogenic factors and

reinforcing the body's resistance. In the present study, *Salvia officinalis* (SO) extract was used for the herbal treatment. To investigate the effect of *Salvia officinalis* on allergic bronchial asthma, the OVA-induced asthmatic mouse model was used.

The cellular infiltrate that characterizes asthma and the ability to control leukocyte migration and eosinophils infiltration into the lungs is viewed as the

key to regulating disease severity. (Lukacs, 2001) . After infiltration at site of allergic inflammation, these inflammatory cells release mediators, e.g., (cytokines and chemokines). *Salvia officinalis* decreased the total leukocyte and eosinophils infiltration in BALF of OVA- induced asthmatic mice. From these results, *Salvia officinalis* may have therapeutic effect in allergic asthma via inhibiting leukocytes and eosinophils migration in the lungs.

Asthma is generally regarded as a T-cell mediated disease. Antigen cause the differentiation of naïve T-cell into helper cells, which then secrete cytokines such as IL-4 and IL-5. IL-4, which is pivotal in the pathogenesis of allergic disorder acts on B cells to facilitate (Switch) IgE production (Haas *et al.*, 1999; Ramshaw *et al.*, 2001). Increased IgE production in response to common environmental antigens is the hallmark of atopic diseases such as bronchial asthma (Hamelmann *et al.*, 1999).

IL-4 also induces the rolling and adhesion of circulating eosinophils to endothelial cells. IL-4, which at least in murine system is essential in instructing B cells to switch to IgE production. Therefore, inhibitors of IL-4 signaling pathway have been suggested as therapeutic targets (Barnes, 2000; Romagnani, 2002).

The present work showed that *Salvia officinalis* (SO) extract significantly decreased IL-4 in BAL. the eosinophils migration observed here showed that (100mg/kg), *Salvia officinalis* extract (SO) caused the reduction of eosinophils infiltration in the BAL and this may be due to decrease in IL-4 by *Salvia officinalis* (SO) extract. Based on these results, it is inferred that *Salvia officinalis* (SO) extract may have an anti-allergic effect on allergic asthma by suppressing IL-4 secretion and, in consequence, inhibiting IgE secretion from lymphocyte B cells. Further, reduced IL-4 may reduce eosinophils infiltration into lungs by inhibition the adhesion of circulating eosinophils to endothelial cells.

IL-5 is a Th2-type cytokine that promotes the recruitment and activation of eosinophils, IL-5 stimulates the release of chemical mediators from eosinophils (Broide 2001). Airway eosinophils inflammation is one of the characteristics of allergic asthma. Therefore IL-5 has been implicated in the pathogenesis of allergic diseases (Rothenberg *et al.*, 1997; Hogen *et al.*, 2001), and many studies appeared that IL-5 is an important target for improved asthma therapy. (Costa *et al.*, 1997; Okudaira and Mori, 1998; VanWauwe *et al.*, 2000). Furthermore, activated Th2- type cells, which can produce IL-5 and several other cytokines, are activated in a greater proportion in asthmatic individuals, in this study, *Salvia officinalis* significantly reduced IL-5 in BAL

and reduced eosinophils infiltration and activation in OVA-induced asthmatic mice.

The present data demonstrate that *Salvia officinalis* can inhibit the excess activity of T- helper cells cytokines which play an important role in the maintenance of bronchial asthma not only by **inhibiting IL-4** production from T cells to suppress IgE production from B cells but also by **reducing IL-5** to decrease eosinophils infiltration.

In addition, histological analysis of lung tissue showed that *Salvia officinalis* inhibited eosinophil infiltration in the lung. From these results, *Salvia officinalis* extract may have therapeutic activity against eosinophilic inflammation in allergic asthma via inhibiting cellular infiltration in the lung.

The control *Salvia officinalis* extract group did not show any considerable differences from the control group this result indicates that *Salvia officinalis* extract does not cause any changes in normal condition, so it does not interrupt the homeostasis of healthy subjects.

Moreover, the present study showed that water extract of *Salvia officinalis* had an anti-inflammatory effect on asthmatic mice induced by OVA.

The anti-inflammatory activity of plant has been attributed to their triterpene (Ghannadi *et al.*, 2005), or flavonoid contents (Palgan and Bartuzi, 2011). Biflavonoids, and triterpenoids produced significant anti-inflammatory activities (La Casa *et al.*, 2000; Calixto *et al.*, 2000 ; Sabu and Kuttan, 2002 ; Silva *et al.*, 2005)

Previous studies showed that *Salvia* species are rich in phenolic compounds, such as phenolic acids and flavonoids, in addition to terpenoids (LaCasa *et al.*, 2000).

Therefore, the presence of anti-inflammatory activity may be due to phenol and terpenoid contents in the plant.

In summary, We conclude that *Salvia officinalis* may be used to bronchial allergic asthma to reduce airways hyperreactivity by suppressing IL-4, IL-5 and IgE. The present data suggest that *Salvia officinalis* (SO) has a therapeutic effect on bronchial asthma by inhibiting T cells activation and reducing eosinophils infiltration in the airway.

References

1. Abu-Darwish MS, Al-Ramamneh EA, Kyslychenko VS, Karpiuk UV. (2012): The antimicrobial activity of essential oils and extracts of some medicinal plants grown in Ash-shoubak region - South of Jordan. Pak J Pharm Sc.i.; 25(1):239-246.
2. American Association for Accreditation of Laboratory Animal Care (AAALAC): The National Academic Press (1996): Appendix B:

- Selected Organizations Related to Laboratory animal Science.
3. Baricevic, D., Bartol, T., (2000): The biological/pharmacological activity of the *Salvia* genus. In: Kintzios, S.E. (Ed.), SAGE - The Genus *Salvia*. Harwood Academic Publishers, Amsterdam, pp. 143-184.
 4. Baricevic D, Sosa S, Della Loggia R, Tubaro A, Simonovska B, Krasna A, Zupancic A. (2001): Topical anti-inflammatory activity of *Salvia officinalis* L. leaves: the relevance of ursolic acid. *J Ethnopharmacol.*; 75(2-3):125-132.
 5. Barnes P. J.(2000) New directions in allergic disease: mechanism-based anti-inflammatory therapies. *J. Allergy. Clin. Immunol*; 106: 5-16.
 6. Bollag U, Grize L, Braun-Fahrlander C. (2009): Is the ebb of asthma due to the decline of allergic asthma? A prospective consultation-based study by the Swiss Sentinel Surveillance Network, 1999–2005. *FamPract.* ; 6: 96–101.
 7. Boyce JA, Bochner B, Finkelman FD, Rothenberg ME. (2012): Advances in mechanisms of asthma, allergy, and immunology in 2011. *J Allergy Clin Immunol.*; 129(2):335-341.
 8. Bozin B, Mimica-Dukic N, Samojlik I, Jovin E (2007). Antimicrobial and antioxidant properties of rosemary and sage (*Rosmarinus officinalis* L. and *Salvia officinalis* L., Lamiaceae) essential oils. *J Agric Food Chem*; 55(19): 7879-85.
 9. Broide, D. H .(2001). Molecular and Cellular mechanisms of allergic disease. *J. Allergy. Clin. Immunol*; 108(Suppl 2): S 65-71.
 10. Calixto AB, Beirith A, Ferreira J *et al.* (2000). Naturally occurring antinociceptive substances from plants. *Phytother Res.* ; 14: 401-418.
 11. Costa, J. J., Weller, P. F., Galli, S. J (1997). The cell of the allergic response: mast cells, basophils, and eosinophils. *JAMA*; 278: 1815-22.
 12. Elias, J.A., C.G. Lee, T. Zheng, B. Ma, R.J. Homer, and Z. Zhu. (2003): New insights into the pathogenesis of asthma. *J. Clin. Invest.*; 111:291–297.
 13. Erb KJ, Holloway JW, Soback A, Moll H, Le Gros G. (1998): Infection of mice with *Mycobacterium bovis*-*Bacillus Calmette-Guérin* (BCG) suppresses allergen-induced airway eosinophilia. *J Exp Med.*; 187(4):561-569.
 14. Gali-Muhtasib, H., C. Hilan and C. Khater (2000). Traditional uses of *Salvia libanotica* (East Mediterranean sage) and the effects of its essential oils. *J. Ethnopharmacol.*; 71(3): 513-520.
 15. Geuenich S, Goffinet C, Venzke S, Nolkemper S, Baumann I, Plinkert P, Reichling J, Keppler OT. (2008): Aqueous extracts from peppermint, sage and lemon balm leaves display potent anti-HIV-1 activity by increasing the virion density. *Retrovirology.* ; 5:27.
 16. Ghannadi A, Hajhashemi V, Jafarabadi H (2005). An investigation of the analgesic and anti-inflammatory effects of *Nigella sativa* seed polyphenols. *J Med Food*; 8: 488-493.
 17. Haas, H., Falcone, F. H., Holland, M. J., Schramm, G., Haisch, K., Gibbs, B. F., *et al.* (1999). Early interleukin-4 its role in the switch towards a Th2 response and IgE-mediated allergy. *Int Arch Allergy Immunol*; 119: 86-94.
 18. Hamelmann E (2007): The rationale for treating allergic asthma with anti-IgE. *European Respiratory Review*; 16: 61–66.
 19. Hamelmann, E., Tateda, K., Oshiba, A., Gelfand, E. W(1999). Role of IgE in the development of allergic airway inflammation and airway hyperresponsiveness- murine model. *Allergy*; 54: 297-305.
 20. Henderson WR Jr, Lewis DB, Albert RK, Zhang Y, Lamm WJ, Chiang GK, Jones F, Eriksen P, Tien YT, Jonas M, Chi EY. (1996): The importance of leukotrienes in airway inflammation in a mouse model of asthma. *J Exp Med.*; 184(4):1483-1494.
 21. Hogan, S. P. Mishra, A., Brandt, E. B., Royalty, M. P., Pope, S. M., Zimmermann, N., *et al* (2001). A pathological function for eotaxin and eosinophils in eosinophilic gastrointestinal inflammation. *Nat. Immunol*; 2: 353-360.
 22. Kay AB (2001): Allergy and allergic diseases First of two parts. *N Engl J Med*,
 23. Kintzios, S.E. (2000). Medicinal and aromatic plants-Industrial profiles, sage, the genus *Salvia*, vol. 14, Harwood Academic Publishers, The Netherlands.
 24. Kumar RK (2001). Understanding airway wall remodeling in asthma : a basis for improvement in therapy? *Pharmacol.Ther.*;91 (2):93-104
 25. Kumperman D., Schofield B., Wills- karp M., and Grusby M.J. (1998):Signal transducer and activator of transcriptions factor 6 (state 6) – deficient mice are protected from antigen-induced airway hyper responsiveness and mucus production. *J.Exp. Med.*;187:939-948.
 26. La Casa C, Villegas I, Alarcon de la Lastra C *et al.* (2000). Evidence for protective and antioxidant properties of rutin, a natural flavones, against ethanol induced gastric lesions. *J Ethnopharmacol*; 71: 45-53,.
 27. Loizzo MR, Tundis R, Menichini F, Saab AM, Statti GA, Menichini F. (2007): Cytotoxic activity of essential oils from labiatae and lauraceae families against in vitro human tumor models. *Anticancer Res.*; 27(5A):3293-3299.

28. Lommatzsch M. (2012): Airway hyperresponsiveness: new insights into the pathogenesis. *Semin Respir Crit Care Med.*; 33(6):579-587.
29. Longaray Delamare, A.P., Moschen-Pistorello, I.T., Artico, L., Atti-Serafini, L., Echeverrigaray, S. (2007). Antibacterial activity of the essential oils of *Salvia officinalis* L. and *Salvia triloba* L. cultivated in South Brazil. *Food Chemistry*; 100: 603–608.
30. Lukacs N. W (2001). Role of chemokines in the pathogenesis of asthma *Nat. Rev. Immunol.*; 1: 108-16.
31. Nolkemper S, Reichling J, Stintzing FC, Carle R, Schnitzler P (2006): Antiviral effect of aqueous extracts from species of the Lamiaceae family against Herpes simplex virus type 1 and type 2 *in vitro*. *Planta Med.*; 72(15):1378-1382.
32. Okudaria, H., Mori, A (1998). Simple understanding and optimistic strategy for coping with atopic diseases. IL-5 central hypothesis on eosinophilic inflammation. *Int. Arch. Allergy Immunol*; 117: 11-19.
33. Palgan K. and Bartuzi Z. (2011): The role of flavonoids in asthma , *Post Dermatol Alergol . XXVIII* ;5:396-401
34. Ramshaw H. S. Woodcock J. M., Bagley. C. T., McClure, B. J., Hercus, T. R., Loperz, A. R (2001). New approaches in the treatment of asthma. *Immunol Cell Biol*; 79: 154-159.
35. Renauld, J.C. (2001): New insights into the role of cytokines in asthma. *J. Clin. Pathol.* 54:577–589.
36. Rodrigues MR, Kanazawa LK, das Neves TL, da Silva CF, Horst H, Pizzolatti MG, Santos AR, Baggio CH, Werner MF. (2012): Antinociceptive and anti-inflammatory potential of extract and isolated compounds from the leaves of *Salvia officinalis* in mice. *J Ethnopharmacol.*; 139 (2):519-526.
37. Romagnani, S.,(2002): Cytokines and chemo attractants in allergic disease. *J. Allergy. Clin. Immunol.*; 38: 881-885.
38. Rothenberg, M. E., MacLcan, J. A., Pearlman E., Luster A. D., Leder, P (1997). Targeted disruption of the chemokine eotaxin partially reduces antigen-induced tissue eosinophilia. *J. Exp. Med.*; 185: 785-90.
39. Sabu MC, Kuttan R (2002). anti-diabetic activity for medicinal plants and its relationship with their antioxidant property. *J Ethnopharmacol*; 81: 155-160.
40. Secor ER, Carson WF, Singh A, Pensa M, Guernsey LA, Schramm CM, Thrall RS. (2008): Oral Bromelain Attenuates Inflammation in an Ovalbumin-induced Murine Model of Asthma. *Evid Based Complement Alternat Med.*; 5(1):61-69.
41. Silva GN, Martins FRF, Matheus ME *et al.* (2005). Investigation of anti-inflammatory and antinociceptive activities of *Lantana trifolia*. *J Ethnopharmacol*; 100: 254-259.
42. Soković M, Glamočlija J, Marin PD, Brkić D, van Griensven LJ. (2010): Antibacterial effects of the essential oils of commonly consumed medicinal herbs using an *in vitro* model. *Molecules.*; 15(11):7532-7546.
43. StockertK,Schneider B, Porenta G, Rath R, Nissel H, Eichler I. Laser acupuncture and probiotics in school age children with asthma : a randomized, principles of Traditional Chinese Medicine. *Pediatr Allergy Immunol* 2007; 18:160-6
44. Van Wauwe J., AertsF., Cools, M., Deroose, F., Freyne, E., Goossens, J., et al(2000). Identification of R146225 as a novel, orally active inhibitor of interleukin-5 biosynthesis *J. Pharmacol. Exp. Ther.*; 295: 655-661.
45. Walsh GM., (2006). Targeting airway inflammation: novel therapies for the treatment of asthma. *Curr Med Chem*:13 (25): 3105-11.
46. Wills-Karp, M. (1999): Immunologic basis of antigen-induced airway hyperresponsiveness. *Annu. Rev. Immunol.* 17:255–281.
47. Yim YK, Lee H, Hong KE, Kim YI, Ko SK, Kim JE, Lee SY, Park KS. (2010): Anti-inflammatory and Immune-regulatory effects of Subcutaneous *Perillae fructus* extract injections on OVA-induced asthma in mice. *Evid Based Complement Alternat Med.*; 7(1):79-86.

10/22/2012